Chinese Journal of Organic Chemistry >
Design and Synthesis of Breast Cancer Susceptibility Gene BRCA1 Analogs Peptides and the Interaction of Analogs Peptides with Breast Cancer Suppressor Gene Protein RAD51
Received date: 2017-08-21
Revised date: 2017-10-26
Online published: 2017-10-31
Supported by
Project supported by the National Natural Science Foundation of China (Nos. 21572046, 21172054).
Peptide breast cancer susceptibility gene BRCA1 plays an active role in inhibiting female breast cancer. The interaction between BRCA1 and breast cancer suppressor gene protein RAD51 in cancer cell is also an essential part for the treatment of breast cancer. Discovery Studio simulation of the docking process of BRCA1 analogs and RAD51 was used to screen the BRCA1 analogs with different charge and acid-base properties. The R-DOCK evaluation system is used to screened out 4 higher BRCA1 like peptides from the results, and the interactions with BRCA1 analogs of RAD51 peptides (Pep158-180, Pep181-200 and Pep241-260) were studied by using fluorescence spectroscopy and CD spectroscopy. The results indicate that acid-base properties of BRCA1 analogs have great influence on their interaction. The results showed that the effect of BRCA1-3 to RAD51 (Pep158-180/Pep241-260) which is the two key peptides were obviously higher than the other parent peptide. Besides, compared with BRCA1, all BRCA1 analogs combined with RAD51 much closer. The results provide evidence to design novel breast drugs for breast cancer.
Key words： BRCA1 peptide; RAD51 peptide; fluorescence; CD spectroscopy; DS simulation
Li Linlu, Lü Mingxiu, Lu Kui, Liu Guangbin, Peng Lu . Design and Synthesis of Breast Cancer Susceptibility Gene BRCA1 Analogs Peptides and the Interaction of Analogs Peptides with Breast Cancer Suppressor Gene Protein RAD51[J]. Chinese Journal of Organic Chemistry, 2018 , 38(1) : 246 -252 . DOI: 10.6023/cjoc201708041
[1] Qiu, J. J.; Hu, Z.; Guan, J. Q. Chin. Nurs. Res. 2017, 31, 303(in Chinese). (裘佳佳, 胡震, 管佳琴, 护理研究, 2017, 31, 303.)
[2] Li, H.; Zhao, W. J.;Cao, S. X.; Lu, K.; Zhao, Y. F. Chem. J. Chin. Univ. 2004, 25, 1866(in Chinese). (李红, 赵文杰, 曹书霞, 卢奎, 赵玉芬, 高等学校化学学报, 2004, 25, 1866.)
[3] Ma, L.; Zhao, D. X.; Ren, H. P.; Lu, K. Asian J. Chem. 2011, 23, 2020.
[4] Coquelle, N.; Green, R. Biochemistry 2011, 50, 4579.
[5] Raderschall, E.; Stout, K.; Freier, S. Cancer Res. 2002, 62, 219.
[6] Zhang, G.; Wang, L.; Zhou, X. J. Agric. Food Chem. 2014, 62, 991.
[7] Ito, M.; Yamamoto, S. Gene 2005, 7, 1044.
[8] Srishailam, A.; Kumar, Y. P.; Gabra, N. M.; Reddy, P. V.; Deepika, N.; Satyanarayana, S. J. Fluoresc. 2013, 23, 897.
[9] Henderson, B. R. Scientifica 2012, 796.
[10] Palma, P. N.; Krippahl, L.; Wampler, J. E. Proteins 2000, 39, 372.
[11] Taylor, J. S.; Burnett, R. M. Proteins 2000, 41, 173.
[12] Relles, H. M.; Schluenz, R. W. J. Org. Chem. 1972, 37, 1742.
[13] Hegde, A. H.; Prashanth, S. N.; Seetharamappa, J. J. Pharm. Biomed. 2012, 63, 40.
[14] Mazin, A. V.; Mazina, O. M.; Bugreev, D. V. DNA Repair 2010, 9, 286.
[15] Matuszak, N.; Muccioli, G. G.; Labar, G. J. Med. Chem. 2009, 52, 7410.
[16] Relles, H. M.; Schluenz, R. W. J. Org. Chem. 1972, 37, 1748.
[17] Shen, X.-C.; Liang, H.; He, X.-W.; Wang, X.-S. Chin. J. Anal. Chem. 2004, 32, 388(in Chinese). (沈星灿, 梁红, 何锡文, 王新省, 分析化学, 2004, 32, 388.)
[18] Zheng, T.; Wang, Z.-Y.; Hou, R.-B.; Shen, X.-C. J. Guangxi Nomal Univ. (Nat. Sci. Ed.) 2008, 26, 57(in Chinese). (郑婷, 王卓渊, 侯若冰, 沈星灿, 广西师范大学学报(自然科学版), 2008, 26, 57.)
[19] Xu, G, He, Q.; Yang, B. Lett. Drug Des. 2009, 6, 51.
[20] Viljakainen, L.; Pamilo, P. J. Mol. Evol. 2008, 67, 643.
[21] Gajski, G.; Garaj, K.; Vrhovac, V. Environ. Toxicol. Pharmacol. 2013, 36, 697.
[22] Zhen, Q.; Cheng, X. D. J. Mol. Biol. 2009, 393, 191.
[23] Li, B. Q. Peptide Drugs Research and Development, Beijing People's Medical Publishing House, Beijing, 2011, p. 37(in Chinese). (厉保秋, 多肽药物研究与开发, 人民卫生出版社, 北京, 2011, p. 37.)
[24] Zhao, D.-X.; Sun, J.; Lu, K. Chem. J. Chin. Univ. 2013, 34, 2114(in Chinese). (赵东欣, 孙静, 卢奎, 高等学校化学学报, 2013, 34, 2114.)
/
| 〈 |
|
〉 |
